NovaBridge Biosciences
NBP
$1.70
-$0.08-4.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.47M | 40.08M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.63M | 109.38M | -- | -- | -- |
| Operating Income | -122.63M | -109.38M | -- | -- | -- |
| Income Before Tax | -117.55M | -104.12M | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -117.55 | -104.12 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.55M | -104.12M | -- | -- | -- |
| EBIT | -122.63M | -109.38M | -- | -- | -- |
| EBITDA | -122.53M | -109.29M | -- | -- | -- |
| EPS Basic | -2.35 | -2.13 | -- | -- | -- |
| Normalized Basic EPS | -0.63 | -0.57 | -- | -- | -- |
| EPS Diluted | -2.35 | -2.13 | -- | -- | -- |
| Normalized Diluted EPS | -0.63 | -0.57 | -- | -- | -- |
| Average Basic Shares Outstanding | 451.20M | 417.18M | -- | -- | -- |
| Average Diluted Shares Outstanding | 196.17M | 181.38M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |